US EditionCombination Therapy Shows 65% Response Rate in Rare Lymphoma
Summary by Inside Precision Medicine
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Combination Therapy Shows 65% Response Rate in Rare Lymphoma
A combination immunotherapy targeting PD-1 and CD38 achieved a 65% objective response rate in patients with relapsed extranodal NK/T-cell lymphoma (ENKTL), according to a multinational Phase II clinical trial by researchers from the National Cancer Centre Singapore (NCCS). The findings, published in Blood, also confirmed that specific genetic markers—including structural variations disrupting the 3′-UTR of the PD-L1 gene—can predict which patien…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
